IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

Study Status Study Restriction

In Development

US & Non-US

What is IMPAACT 2028?

IMPAACT 2028 is an observational study to characterize a cohort of children who may participate in future research related to HIV remission or cure. Children in this study will have previously received early or very early treatment for HIV in other IMPAACT studies or other studies sponsored by the United States National Institutes of Health. Children in this study will complete study visits approximately every six months at which key clinical, immunologic, and virologic outcomes will be assessed for a period of up to seven years.

Sites where the study is implemented:

CRS ID Site Name City Country
Site Selection in progress.

Study contacts:

Study Chair: Shaun Barnabas

Study Vice-Chair: Samantha Fry

Study Vice-Chair: Julia Rosebush

DAIDS Medical Officer: Hans Spiegel

DAIDS Medical Officer: Dwight Yin

NICHD Medical Officer: Eric Lorenzo

Clinical Trials Specialist: Anne Coletti

Data Manager: Christina Reding

Data Manager: Yvonne Woolwine-Cunningham

Epidemiologist: Kunjal Patel

Immunologist: Alka Khaitan

Immunologist: Adriana Weinberg

Investigator: Ellen Chadwick

Investigator: Mark Cotton

Laboratory Data Manager (LDM): Colleen Foley

Laboratory Data Manager (LDM): Jared Kneebone

Laboratory Specialist: Diane Costello

Laboratory Technologist: Paul Harding

Laboratory Technologist: Jason Rippe

Statistician: Bryan Nelson

Virologist: Deborah Persaud

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.